Abstract: A tool device, such as a lawnmower, or a steerable-wheel assembly therefor may include a frame, a walking element, a drive motor, and a steerable-wheel assembly (SWA). The walking element may be coupled to the frame. The drive motor may selectively power the walking element. The SWA may be attached to the frame apart from the walking element. The SWA may include a caster connector pivotably mounted to the frame to rotate about a pivot axis, a steerable wheel rotatably coupled to the caster connector, a primary drive gear, a primary driven gear, and a secondary driven gear.

Abstract: A tool device, such as a lawnmower, or a steerable-wheel assembly therefor may include a frame, a walking element, a drive motor, and a steerable-wheel assembly (SWA). The walking element may be coupled to the frame. The drive motor may selectively power the walking element. The SWA may be attached to the frame apart from the walking element. The SWA may include a caster connector pivotably mounted to the frame to rotate about a pivot axis, a steerable wheel rotatably coupled to the caster connector, a detectable magnet fixed to the caster connector to pivot therewith about the pivot axis, and an encoder including a magnetic sensor fixed to the frame apart from the caster connector to detect a pivotable position of the detectable magnet.

Abstract: The disclosure provides new transdermal pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: Systems and methods facilitate sensing and tallying defecation events of subjects, such as participants in clinical trials for treatments for treating digestive diseases, such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and chronic constipation. Systems and methods may also be used by individual patients for sensing and tallying defecation events, and resulting data may be reviewed by a healthcare provider when evaluating patient gastrointestinal health and/or treatments.

Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.

Abstract: A method of manufacturing a patient transfer system including obtaining an inflatable device, where the device includes a top sheet of material and a bottom sheet of material connected to the top sheet of material defining a cavity therebetween to be inflated. The device further includes a plurality of passages in the bottom sheet extending from the cavity to an exterior of the device, where the passages are configured to permit air to pass from the cavity to the exterior of the device. The device also including a plurality of inflation-limiting members connecting the top sheet and bottom sheet, and an input configured for receiving air to inflate the device. The method further includes providing an absorbent body pad with the inflatable device, the absorbent body pad configured to be positioned between the top sheet of material and a patient positioned on the inflatable device.

Abstract: Methods, devices and systems are disclosed for inter-app communications between software applications on a mobile communications device. In one aspect, a computer-readable medium on a mobile computing device comprising an inter-application communication data structure to facilitate transitioning and distributing data between software applications in a shared app group for an operating system of the mobile computing device includes a scheme field of the data structure providing a scheme id associated with a target software app to transition to from a source software app, wherein the scheme id is listed on a scheme list stored with the source software app; and a payload field of the data structure providing data and/or an identification where to access data in a shared file system accessible to the software applications in the shared app group, wherein the payload field is encrypted.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: A refuse vehicle includes a chassis, a body, a lock, a tailgate, an ejector, an actuator, a second actuator, and a processor. The body defines a receptacle for storing refuse. The lock is coupled to the body and is configured to releasably secure a movable tailgate. The receptacle contains the ejector. The ejector can transition from a first position that is spaced from the tailgate to a second position proximate the tailgate. The actuator is configured to transition the ejector from the first position to the second position. The second actuator is configured to move the tailgate. The processor is configured to selectively unlock the tailgate and transition the ejector from the first position to the second position in response to receiving a single input to thereby eject refuse from the receptacle without receiving multiple inputs.

Abstract: A range extension system for a refuse vehicle includes a battery, and a controller. The battery is configured to provide electrical energy for accessories of the refuse vehicle. The controller is configured to obtain a state of charge of the battery and limit operation of at least one of the accessories in response to the state of charge of the battery to extend a transportation range of the refuse vehicle.

Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.

Abstract: A refuse vehicle includes multiple tractive elements, a prime mover, and an independent accessory system. The prime mover is configured to generate mechanical energy to drive one or more of the tractive elements. The independent accessory system includes one or more storage tanks configured to store a fuel, and an accessory primary mover. The accessory primary mover is configured to fluidly couple with the one or more storage tanks to receive the fuel from the one or more storage tanks and operate to pressurize a hydraulic fluid to drive an accessory of the refuse vehicle. The accessory primary mover is configured to pressurize the hydraulic fluid to drive the accessory of the refuse vehicle independently of operation of the prime mover.

Abstract: The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A/mu-opioid receptor or 5-HT2A/D1 and/or D2/mu-opioid receptor ligand.

Abstract: An apparatus, system and related methods for controlling a pressurized flow from a high or low pressure system. An actuated sand dump system and related methods include a first valve positioned downstream of a high or low pressure system, a second valve positioned downstream of the first valve, a choke positioned between in the first and second valves, a plurality of pressure gauges, and a control unit operable to automatically open and close the first and second valves and the choke in a predetermined sequence, upon initiating the predetermined sequence, and in response to pressure measurements from the plurality of pressure gauges.

Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.

Abstract: According to an aspect of the present invention disclosed herein, there is provided buckle, comprising: a male component and a female component, wherein: the male component comprises: a slot for a strap at an end of the male component opposite the side where the male component is configured to insert into the female component; an inclined insert; and one or more mating slots in the inclined insert; and the female component comprises: a top wall, a bottom wall, and sidewalls forming a receiving portion; a plurality of teeth; a slot for a strap; and a chord, wherein the chord is configured that when pulled the teeth disengage just enough for the male component to be released.

Abstract: One embodiment of a method for reducing network congestion cause by multicast communications includes receiving, via a network, first data associated with one or more multicast operations, determining a congestion state of the network based on the first data, and performing one or more operations to reduce an amount of second data that is transmitted via the network based on the congestion state of the network.

Abstract: A refuse vehicle includes a chassis, a vehicle body supported by the chassis, a lift assembly, and a projector. The vehicle body defines a receptacle for storing refuse. The lift assembly is configured to selectively engage a waste container. The lift assembly is movable between a first position and a second position. The projector is positioned to emit light outwardly away from the refuse vehicle and proximate the lift assembly to define a target area.

Abstract: The present disclosure relates to a composition that includes a poly(hydroxy)urethane (PHU) foam, a phase change material (PCM), and a solid additive, where the PHU foam includes a plurality of voids, at least a portion of the voids contain the PCM and the solid additive, and the composition is capable of being repeatedly cycled through a temperature range, resulting in the PCM cycling between a solid phase and a liquid phase. In some embodiments of the present disclosure, the PCM may include at least one of a hydrated salt, a paraffin wax, a sugar alcohol, a fatty acid, and/or a eutectic mixture.

Abstract: A refuse vehicle includes a chassis, an energy storage device, a body, an electric power take-off system, and a disconnect. The energy storage device is supported by the chassis and is configured to provide electrical power to a prime mover. Activation of the prime mover selectively drives the refuse vehicle. The body is supported by the chassis and defines a receptacle for storing refuse. The electric power take-off system is positioned on the refuse vehicle, and includes a motor that is configured to drive a hydraulic pump to convert electrical power received from the energy storage device into hydraulic power. The disconnect is positioned between the energy storage device and the electric power take-off system and is configured to selectively decouple the electric power take-off system from the energy storage device.